CD34+ Cells in the Blood of Patients With Multiple Myeloma Express CD19 and IgH mRNA and Have Patient-Specific IgH VDJ Gene Rearrangements
Open Access
- 1 March 1997
- journal article
- Published by American Society of Hematology in Blood
- Vol. 89 (5) , 1824-1833
- https://doi.org/10.1182/blood.v89.5.1824
Abstract
Peripheral blood mononuclear cells (PBMC) from patients with multiple myeloma (MM) are here shown to include 23% ± 2% of CD34+ cells, the majority of which coexpress CD19, as identified by a panel of 17 anti-CD34 antibodies. The expression of CD34 mRNA by sorted CD34+ PBMC from MM was confirmed by in situ reverse transcriptase-polymerase chain reaction (RT-PCR) with CD34-specific primers. The majority of CD34+ MM PBMC were CD19+ cells that expressed mRNA for CD19 and for rearranged IgH as identified with consensus IgH VDJ primers, as well as having cytoplasmic Ig, definitively identifying them as B cells, in absolute numbers of 0.06 to 0.69 × 109/L of blood. CD34 is largely absent from normal B cells. To determine the clonal relationship of CD34+ B cells to autologous MM plasma cells, IgH VDJ DNA rearrangements of sorted CD34+ MM blood B cells were amplified by nested PCR using consensus primers followed by Southern blotting with allele-specific oligonucleotides for 7 MM patients, and clonotypic IgH mRNA expression was assessed for 4 MM patients using quantitative patient-specific in situ RT-PCR. For 9 of 11 myeloma patients tested, CD34+ blood B cells included IgH gene rearrangements or expressed IgH mRNA identical to that of autologous bone marrow plasma cells. For 4 of 4 MM patients, 74% to 94% of individual sorted CD34+19+ B cells expressed clonotypic IgH mRNA, as detected by in situ RT-PCR with patient-specific primers. Clonotypic IgH VDJ sequences were absent from B cells of unrelated MM patients and of normal donors. Clonotypic CD34+ B cells were detected before, during, and after treatment, and during relapse. Our results indicate a clonal relationship between CD34+ MM B cells and malignant plasma cells. We speculate that CD34 may play an important role in the biology of myeloma by facilitating extravasation from blood and thus spread of myeloma through the skeletal system.Keywords
This publication has 31 references indexed in Scilit:
- Circulating Clonotypic B Cells in the Biology of Multiple Myeloma: Speculations on the Origin of MyelomaLeukemia & Lymphoma, 1996
- Intrinsic Expression of the Multidrug Transporter, P-Glycoprotein 170, in Multiple Myeloma: Implications for TreatmentLeukemia & Lymphoma, 1995
- In vitro and in vivo antitumour activity of a chimeric anti-CD19 antibodyCancer Immunology, Immunotherapy, 1995
- Certain anti‐CD34 monoclonal antibodies induce homotypic adhesion of leukemic cell lines in a CD18‐dependent and a CD18‐independent wayEuropean Journal of Immunology, 1994
- RHAMM, a Receptor for Hyaluronan-Mediated Motility, on Normal Human Lymphocytes, Thymocytes and Malignant B Cells: a Mediator in B cell Malignancy?Leukemia & Lymphoma, 1994
- Expression of multiple β1 integrins on circulating monoclonal B cells in patients with multiple myelomaAmerican Journal of Hematology, 1993
- Restricted Expression of Immunoglobulin Light Chain mRNA and of the Adhesion Molecule CD11b on Circulating Monoclonal B Lineage Cells in Peripheral Blood of Myeloma PatientsScandinavian Journal of Immunology, 1992
- The CD34 Antigen: Structure, Biology, and Potential Clinical ApplicationsJournal of Hematotherapy, 1992
- Preparation and characterization of a chimeric CD 19 monoclonal antibodyImmunology & Cell Biology, 1991
- Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.Journal of Clinical Investigation, 1985